VivoSeq
Other

Soft Tissue Infections

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Soft Tissue Infections is an early-stage landscape with 0 programs across 2 companies. The most active players are Novartis, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed8 · 73%
Unknown status1 · 9%
Terminated1 · 9%
No longer available1 · 9%

Clinical Trials

Trial Activity

11 trials

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·N/A·NCT00475930·1,563 enrolled
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 2·NCT03637400·269 enrolled
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT03643952·18 enrolled
A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who Inject Drugs
Completed·—·Phase 4·NCT06733506·56 enrolled
Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections
Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT00428818·75 enrolled
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Completed·AAtox Bio Ltd·Phase 3·NCT02469857·290 enrolled
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
Completed·AAtox Bio Ltd·Phase 2·NCT01417780·43 enrolled
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
Completed·Novartis logoNovartis·Phase 3·NCT01184872·120 enrolled
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
Terminated·Novartis logoNovartis·Phase 3·NCT00430937·194 enrolled
Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department
Unknown status·UUniversity of British Columbia·Phase 3·NCT00323219·390 enrolled
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
No longer available·SSonescence, Inc.·N/A·NCT01238276

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)